Author

A. Dobrin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:bacteria (other)· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Chow· 1 shared A. Farillas· 1 shared A. Holland· 1 shared A. Kulick· 1 shared A. Quintanal-Villalonga· 1 shared A. Richards· 1 shared C. A. Klebanoff· 1 shared C. Kwong· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Chow

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Metabolic connections between folate and peptidoglycan pathways in Pseudomonas aeruginosa inform rational design of a dual-action inhibitor

L. N. Yaeger, D. Sycantha, P. Luong, S. Shekarriz, O. Goncalves, A. Dobrin, M. R. Ranieri, R. P. Lamers, H. Harvey, G. C. diCenzo, M. G. Surette, J.-P. Cote, J. Magolan, L. L. Burrows

This study identifies metabolic links between folate and peptidoglycan pathways in Pseudomonas aeruginosa and uses these insights to design a dual-action inhibitor that overcomes antibiotic resistance.

bioRxiv · Nov 22, 2023 · PreprintMicrobiology

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

A. Chow, F. Z. Uddin, L. Mangarin, H. Rizvi, A. Dobrin, S. E. Tischfield, A. Quintanal-Villalonga, J. M. Chan, N. S. Shah, V. Allaj, P. Manoj, M. Mattar, M. Meneses, M. Liu, R. Landau, , C. M. Rudin

This study identifies CD39 as a marker for tumor-reactive CD8 T cells in lung cancer, showing its association with clinical outcomes and response to immune checkpoint therapy.

bioRxiv · Jan 24, 2022 · PreprintImmunology